Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Toni K. Choueiri*, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar, Luis E. Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu Lin Chang, Maximiliano Van Kooten Losio, Cristina Suarez, Robert J. Motzer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences